期刊文献+

2009-2011年上海医院抗肿瘤用药分析 被引量:5

Analysis of the medication on anticancer drugs in Shanghai sample hospitals from 2009 to 2011
暂未订购
导出
摘要 目的:了解2009-2011年上海医院抗肿瘤药物临床应用,供生产、营销和使用等部门参考。方法:根据上海119家样本医院提供的2009-2011年抗肿瘤用药数据,3年比较,结合临床应用进行分析讨论。结果:近年来抗肿瘤药物需求量迅速增长,常用品种有多西他赛、奥沙利铂、紫杉醇、吉西他滨、培美曲塞和卡培他滨等,中药制剂有"爱迪"、复方斑蝥等,新型靶向药物有曲妥珠单抗、利妥昔单抗等。结论:开发高效、低毒、价廉的抗肿瘤药物是当今迫切的任务。 Objective: To investigate the clinical application of anticancer drugs in Shanghai sample hospitals during 2009-2011 so as to provide a refrence for the production, marketing and application and so on. Methods: The data on anticancer drugs used in 119 Shanghai sample hospitals were compared and analyzed in respect to the clinical applications. Results: The demand for anticancer drugs had been rapidly growing. The main varieties are docetaxel, oxaliplatin, paclitaxel, gemcitabine, pemetrexed and capecitabine, etc. Traditional Chinese medicine preparations are Adie, Fufang Banmao, etc. The novel targeted drugs are trastuzumab, rituximab, etc. Conclusion: It is the most urgent task to develop the effective, safe and inexpensive anticancer drugs.
出处 《上海医药》 CAS 2013年第11期27-30,共4页 Shanghai Medical & Pharmaceutical Journal
关键词 抗肿瘤药物 上海样本医院 用药变化趋势 anticancer drugs Shanghai sample hospitals medication tendency
  • 相关文献

参考文献6

  • 1卫生部.中国癌症预防与控制规划纲要(2004-2010)[M].北京:人民卫生出版社,2009:1-5.
  • 2陈新谦,金有豫,汤光.新编药物学[M].17版.北京:人民卫生出版社,2011:3465.
  • 3Bianco R, Melisi D, Ciardiello F, et al. Key cancer cell signal transduction pathways as therapeutic targets[J]. Eur J Cancer, 2006, 42(3): 290-294.
  • 4Kalofonos HP, Grivas PD. Monoclonal antibodies in the management of solid tumors[J]. Curr Top Med Chem, 2006, 6(16): 1687-1705.
  • 5勇威本.利妥昔单抗治疗B细胞淋巴瘤现状[J].世界临床药物,2007,28(5):274-277. 被引量:7
  • 6张阳,张力.永无止境的探索——从临床研究看肺癌研究的新进展[J].中国处方药,2007,6(8):61-62. 被引量:3

二级参考文献10

  • 1Kaminski M S,Tuck M,Estes J,et al.131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma[].The New England Journal of Medicine.2005
  • 2Conconi A,Martinelli G,Thieblemont C,et al.Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type[].Blood.2003
  • 3Gopal AK,Gooley TA,Maloney DG,et al.High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma[].Blood.2003
  • 4Cheson BD.Radioimmunotherapy of non-Hodgkin lymphomas[].Current Drug Targets.2006
  • 5Marcus R,Imrie K,Belch A,et al.CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma[].Blood.2005
  • 6Hiddemann W,Kneba M,Dreyling M,et al.Frontline therapy with rituximab addedto the combination of cyclophosphamide,doxorubicin,vincrestine,and prednisone(CHOP)significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone[].Blood.2005
  • 7Gheilmini M,Schimitz SF,Cogliatti SB,et al.Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x4schedule[].Blood.2004
  • 8Czuczman MS,Weaver R,Alkuzweny B,et al.Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy:9-year follow-up[].Journal of Clinical Oncology.2004
  • 9Witzig TE,Flinn IW,Gordon LI,et al.Treatment.with ibritumomab tiuxetan radioimmunotherapy inpatients with rituximab-refractory follicular non-Hodgkin’s lymphoma[].Journal of Clinical Oncology.2002
  • 10Lenz G,Dreyling M,Hoster E,et al.Immunochemotherapy with rituximab and cyclophosphamide,doxorubicin,vincristine,and prednisone significantly improves response and time to treatment failure,but not long-term outcome in patients with previously untreated mantle cell lymphoma[].Journal of Clinical Oncology.2005

共引文献848

同被引文献64

引证文献5

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部